Pentraxin-3 and Presepsin ki sepsis ke nidaan me upyogita
Not Applicable
- Conditions
- Health Condition 1: A499- Bacterial infection, unspecified
- Registration Number
- CTRI/2021/09/036689
- Lead Sponsor
- AIIMS JODHPUR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult patients having clinical features suggestive of sepsis
Exclusion Criteria
Exclusion criteria are age < 18 years, patients with terminal stage of disease (malignant cancer of any type, acquired immunodeficiency syndrome, end-stage liver or renal disease) patient who have received antibiotics and patient/relatives who will not consent to inclusion.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study Changes in Pentraxin-3 and Presepsin levels in patients with sepsis during first week of ICU admissionTimepoint: Day 1 <br/ ><br>3 <br/ ><br>7 <br/ ><br>death or discharge
- Secondary Outcome Measures
Name Time Method 1.To study the utility of Pentraxin-3 and Presepsin with prognosis of sepsis using sequential organ failure assessment (SOFA) score <br/ ><br>2.To study the sensitivity and specificity of Pentraxin-3 and Presepsin for 28 day mortality in critically ill patients <br/ ><br>3.To compare Pentraxin-3 and Presepsin with Procalcitonin in ICU patients with sepsis <br/ ><br>Timepoint: Day 1 <br/ ><br>3 <br/ ><br>7 <br/ ><br>28 <br/ ><br>death or discharge